Cardiovascular autonomic neuropathy (CAN) is one of the most overlooked of the serious complications of diabetes. CAN causes damage to the autonomic nerve fibers that excites the heart and blood vessels, resulting in abnormalities in heart rate control and vascular dynamics.
A recent article shows an association of glycated albumin and CAN development in type 2 diabetic patients. It investigated the relationship of cardiovascular autonomic neuropathy (CAN) with glycated albumin (GA) and with HbA1c fluctuations in type 2 diabetic patients. The study included 498 type 2 diabetic patients initially without CAN. GA and HbA1c levels were regularly measured over 2 years. 53 subjects (10.6%) developed CAN over the 2-year period. Results of the study indicated that GA and HbA1c levels were significantly higher in subjects with CAN. Moreover, higher serum GA rather than HbA1c was more significantly associated with CAN. Also the predictive power of GA is increased when combined with HbA1c.
The study thus demonstrates a new potential for GA as an indicator of CAN in type 2 diabetic patients in addition to the established role of GA in monitoring diabetic complications.
Epinex has been at the forefront in advocating a role for Glycated Albumin for early detection, screening and monthly monitoring of diabetes. Epinex has a patented rapid test, G1A, for Glycated Albumin and is working towards developing this test for clinical trials. This G1A tests measures total albumin and glycated albumin exclusively (not fructosamine), in a hand held device as a POCT (Point of Care Test) for doctors’ offices and clinics, and as an OTC (Over The Counter) test for general public use.